Phibro Animal Health Corporation
NASDAQ:PAHCDrug Manufacturers - Specialty & Generic
+$0.38 today
- Market cap
- $1.44B
- Beta
- 0.46
- P/E (TTM)
- 13.3
- EPS (TTM)
- $2.35
- Dividend yield
- 1.54%
Volume 0.11M
Average 0.37M
PAHC Pre-Tax Margin
Income before tax as a percentage of revenue.
Phibro Animal Health CorporationNASDAQ: PAHC
Pre-Tax Margin · Q3 FY2026 · quarter ended Mar 2026
Pre-tax margin holds steady near 8.4%
Pre-tax margin was 8.4% in Q3 FY2026, down 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 8.6%, up 4.3 pp year over year. Over 3 fiscal years it narrowed by 2.4 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 5.2%
- Year-over-year change
- +4.2pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 5.2% | +4.2pp |
| FY2024 | 2024-06-30 | 1.1% | -4.5pp |
| FY2023 | 2023-06-30 | 5.5% | -2.1pp |
| FY2022 | 2022-06-30 | 7.7% | -0.3pp |
| FY2021 | 2021-06-30 | 8.0% | — |
Pre-Tax Margin vs competitors
How PAHC compares with its peers on the latest reported figures
- PAHC's LTM Mar 2026 pre-tax margin of 8.6% is the 3rd highest of the 6 companies compared; the peer median is -1.8%.
- Its year-over-year change of +4.3 pp is the 2nd highest of 6, against a peer median of -1.4 pp.
- Over three fiscal years its change of -2.4 pp compares with a peer median of +1.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 34.4% | -1.0 pp | +2.6 pp | |
| LTM Jun 2026 | 9.0% | -21.1 pp | +4.7 pp | |
| LTM Mar 2026 | 8.6% | +4.3 pp | -2.4 pp | |
| LTM Sep 2026 | -1.8% | -1.4 pp | -3.1 pp | |
| LTM Aug 2026 | -7.7% | +113.4 pp | +1.6 pp | |
| FY2025 | -61.8% | -69.5 pp | -86.3 pp | |
| Peer median (excluding PAHC) | -1.8% | -1.4 pp | +1.6 pp | |
Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 833.35M | 942.26M | 977.89M | 1.02B | 1.3B |
| Cost of Revenue | 561.97M | 656.86M | 679.65M | 704.59M | 896.27M |
| Gross Profit | 271.38M | 285.4M | 298.24M | 313.09M | 399.94M |
| Gross Margin | 32.6% | 30.3% | 30.5% | 30.8% | 30.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M |
| Operating Expenses | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M |
| Depreciation & Amortization | 31.88M | 32.71M | 34.01M | 36.18M | 45.61M |
| EBITDA | 110.21M | 117.13M | 106.03M | 69.06M | 146.85M |
| EBITDA Margin | 13.2% | 12.4% | 10.8% | 6.8% | 11.3% |
| Operating Income | 74.87M | 78.99M | 71.85M | 53.32M | 110.47M |
| Operating Margin | 9.0% | 8.4% | 7.3% | 5.2% | 8.5% |
| Interest Income | 838K | 816K | 3.36M | 4.47M | 2.62M |
| Interest Expense | 10.4M | 12.1M | 17.95M | 21.97M | 33.25M |
| Other Income / Expenses | (8.4M) | (6.66M) | (17.78M) | (42.4M) | (42.47M) |
| Income Before Tax | 66.47M | 72.33M | 54.07M | 10.92M | 67.99M |
| Pre-Tax Margin | 8.0% | 7.7% | 5.5% | 1.1% | 5.2% |
| Income Tax Expense | 12.08M | 23.15M | 21.47M | 8.5M | 19.73M |
| Net Income | 54.39M | 49.18M | 32.61M | 2.42M | 48.26M |
| Net Margin | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
| EPS (Basic) | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| EPS (Diluted) | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| Weighted Avg Shares | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M |
| Weighted Avg Shares (Diluted) | 40.5M | 40.5M | 40.5M | 40.52M | 40.7M |
Phibro Animal Health Corporation
NASDAQ:PAHC
Intrinsic Alpha fair value
Locked
Current Price
$35.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.